Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Ed Schuuring"'
Autor:
Betzabel N. Cajiao Garcia, Léon C. van Kempen, Chantal C.H.J. Kuijpers, Ed Schuuring, Stefan M. Willems, Anthonie J. van der Wekken
Publikováno v:
Lung Cancer, 167, 1-7. ELSEVIER IRELAND LTD
OBJECTIVES: The recent accelerated FDA approval of sotorasib, a highly selective KRAS G12C inhibitor, offers new opportunities for the treatment of KRAS p.(G12C)-mutated non-squamous non-small cell lung cancer (NSCLC). The objective of the current st
Autor:
Elisabeth M.P. Steeghs, Harry J.M. Groen, Ed Schuuring, Mieke J. Aarts, Ronald A.M. Damhuis, Quirinus J.M. Voorham, Marjolijn J.L. Ligtenberg, Katrien Grünberg
Publikováno v:
Lung Cancer, 167, pp. 87-97
Lung Cancer, 167, 87-97
Lung Cancer, 167, 87-97. ELSEVIER IRELAND LTD
Lung Cancer, 167, 87-97
Lung Cancer, 167, 87-97. ELSEVIER IRELAND LTD
Contains fulltext : 252010.pdf (Publisher’s version ) (Open Access) OBJECTIVES: The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-expanding and requires testing of an increasing number of predictive biomarkers. We present a
Autor:
Karen Zwaenepoel, Kaat Van Casteren, Joke Breyne, Etienne Rouleau, Elisabeth Dequeker, Kelly Dufraing, Nicky D'Haene, Claude Van Campenhout, Ed Schuuring, Jan H. von der Thüsen, Sara Vander Borght
Publikováno v:
BMC Cancer, 22:736. BMC
BMC cancer
BMC Cancer, 22(1):736. BioMed Central Ltd.
BMC cancer
BMC Cancer, 22(1):736. BioMed Central Ltd.
Background For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test conclusio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d095f7c53f313d87f20504da8a0a8b0
https://research.rug.nl/en/publications/baa504ca-1487-4d15-989f-fc0641160a64
https://research.rug.nl/en/publications/baa504ca-1487-4d15-989f-fc0641160a64
Autor:
Kiki C. Andree, Menno Tamminga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Leon W.M.M. Terstappen, Anouk Mentink, Hilda van den Bos, Peter M. Lansdorp, Wim Timens, Diana C.J. Spierings
Publikováno v:
British journal of cancer, 126, 409-418. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be ob
Autor:
Sabrina Weber, Harry J.M. Groen, Hylke C. Donker, Paul van der Leest, T. Jeroen N. Hiltermann, Menno Tamminga, Ellen Heitzer, Thomas Schlange, Grigory Sidorenkov, Wim Timens, Leon W.M.M. Terstappen, Ed Schuuring, Michael R. Speicher, Samantha O Hasenleithner, Ricarda Graf, Tina Moser, Benjamin Spiegl, Marie-Laure Yaspo
Publikováno v:
JCO Precision Oncology, 5(5), 1540-1553. AMER SOC CLINICAL ONCOLOGY
JCO Precision Oncology, 5, 1540-1553. American Society of Clinical Oncology
JCO Precision Oncology, 5, 1540-1553. AMER SOC CLINICAL ONCOLOGY
JCO Precision Oncology, 5, 1540-1553. American Society of Clinical Oncology
JCO Precision Oncology, 5, 1540-1553. AMER SOC CLINICAL ONCOLOGY
PURPOSE Immune checkpoint inhibitors (ICIs) are increasingly being used in non–small-cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated if on-treatment changes of circulating tumor DNA (ctDNA) from ICI start
Publikováno v:
Lung Cancer, 170, 52-57. ELSEVIER IRELAND LTD
Objectives: Predicting the outcome of immunotherapy-treated non-small cell lung cancer (NSCLC) patients is challenging. Measuring circulating tumor DNA (ctDNA) in plasma is promising, but its application for outcome delineation needs further refineme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc8a7a84a1c5f5096f741422a2f7d88
https://research.rug.nl/en/publications/e7d58caf-7f0d-4425-93f3-05d9adbae458
https://research.rug.nl/en/publications/e7d58caf-7f0d-4425-93f3-05d9adbae458
Autor:
Henri B. Wolff, Elisabeth M.P. Steeghs, Zakile A. Mfumbilwa, Harry J.M. Groen, Eddy M. Adang, Stefan M. Willems, Katrien Grünberg, Ed Schuuring, Marjolijn J.L. Ligtenberg, Bastiaan B.J. Tops, Veerle M.H. Coupé
Publikováno v:
JCO Precision Oncology, 6
JCO Precision Oncology, 6:e2200201. AMER SOC CLINICAL ONCOLOGY
JCO Precision Oncology, 6:e2200201. AMER SOC CLINICAL ONCOLOGY
PURPOSE A large number of targeted treatment options for stage IV nonsquamous non–small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is therefore important to optimize diagnostic testing strategies, such that pat
Autor:
Yuanjing Hu, Ya He, Yixin Liu, Ed Schuuring, Ate G.J. van der Zee, G. Bea A. Wisman, Na Li, Xinying Zhang
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 1768-1777. Wiley
STARTPAGE=1768;ENDPAGE=1777;ISSN=0020-7136;TITLE=International Journal of Cancer
International Journal of Cancer, 1768-1777. Wiley
STARTPAGE=1768;ENDPAGE=1777;ISSN=0020-7136;TITLE=International Journal of Cancer
Objective strategies are required in cervical cancer screening. We have identified several DNA methylation markers with high sensitivity and specificity to detect cervical intraepithelial neoplasia 2 or worse (CIN2+) in Dutch women. Our study aims to
Autor:
Nienke Solleveld, Arja ter Elst, Hans Gelderblom, Jan H. von der Thüsen, Ernst-Jan M. Speel, Ed Schuuring, Harry J.M. Groen, Berber Piet, Wendy W.J. de Leng, Anthonie J. van der Wekken, Katrien Grünberg, Stefan M. Willems, Leonie I. Kroeze, Tom E. J. Theunissen, Adrianus J. de Langen, Léon C van Kempen, Lizza E.L. Hendriks, Sayed M S Hashemi, Bart Koopman, Marthe S. Paats, Anne S R van Lindert, Ruud W. J. Meijers, Niven Mehra, Kim Monkhorst, Daniëlle A M Heideman, Winand N.M. Dinjens, Mirjam C. Boelens, Marjolijn J. L. Ligtenberg, Tom van Wezel, Wim Timens, Teodora Radonic
Publikováno v:
Oncologist, 26(8), E1347-E1358. AlphaMed Press
Koopman, B, Groen, H J M, Ligtenberg, M J L, Grünberg, K, Monkhorst, K, de Langen, A J, Boelens, M C, Paats, M S, von der Thüsen, J H, Dinjens, W N M, Solleveld, N, van Wezel, T, Gelderblom, H, Hendriks, L E, Speel, E J M, Theunissen, T E, Kroeze, L I, Mehra, N, Piet, B, van der Wekken, A J, Ter Elst, A, Timens, W, Willems, S M, Meijers, R W J, de Leng, W W J, van Lindert, A S R, Radonic, T, Hashemi, S M S, Heideman, D A M, Schuuring, E & van Kempen, L C 2021, ' Multicenter comparison of Molecular Tumor Boards in the Netherlands : definition, composition, methods and targeted therapy recommendations ', The Oncologist, vol. 26, no. 8, pp. e1347-e1358 . https://doi.org/10.1002/onco.13580
The Oncologist, 26(8), e1347-e1358. AlphaMed Press
The Oncologist, 26(8). ALPHAMED PRESS
Oncologist, 26, 8, pp. e1347-e1358
Oncologist, 26(8), e1347-e1358. AlphaMed Press
The Oncologist, 26(8), e1347-e1358. WILEY
Oncologist, 26, e1347-e1358
The Oncologist
Koopman, B, Groen, H J M, Ligtenberg, M J L, Grünberg, K, Monkhorst, K, de Langen, A J, Boelens, M C, Paats, M S, von der Thüsen, J H, Dinjens, W N M, Solleveld, N, van Wezel, T, Gelderblom, H, Hendriks, L E, Speel, E J M, Theunissen, T E, Kroeze, L I, Mehra, N, Piet, B, van der Wekken, A J, Ter Elst, A, Timens, W, Willems, S M, Meijers, R W J, de Leng, W W J, van Lindert, A S R, Radonic, T, Hashemi, S M S, Heideman, D A M, Schuuring, E & van Kempen, L C 2021, ' Multicenter comparison of Molecular Tumor Boards in the Netherlands : definition, composition, methods and targeted therapy recommendations ', The Oncologist, vol. 26, no. 8, pp. e1347-e1358 . https://doi.org/10.1002/onco.13580
The Oncologist, 26(8), e1347-e1358. AlphaMed Press
The Oncologist, 26(8). ALPHAMED PRESS
Oncologist, 26, 8, pp. e1347-e1358
Oncologist, 26(8), e1347-e1358. AlphaMed Press
The Oncologist, 26(8), e1347-e1358. WILEY
Oncologist, 26, e1347-e1358
The Oncologist
Background Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in
Autor:
T. Jeroen N. Hiltermann, Pei Meng, Jiacong Wei, Martijn Terpstra, Ali Saber, Klaas Kok, Wim Timens, Ed Schuuring, Jantine Sietzema, Anna A. Rybczynska, Anke van den Berg, Anthonie J. van der Wekken, Harry J.M. Groen
Publikováno v:
Cancers, 12(10):2843, 1-17. MDPI AG
Cancers
Cancers, Vol 12, Iss 2843, p 2843 (2020)
Volume 12
Issue 10
Cancers
Cancers, Vol 12, Iss 2843, p 2843 (2020)
Volume 12
Issue 10
The number of genomic aberrations known to be relevant in making therapeutic decisions for non-small cell lung cancer patients has increased in the past decade. Multiple molecular tests are required to reliably establish the presence of these aberrat